An Early Exploratory Clinical Study of the Safety, Tolerability, and Initial Efficacy of JY231 Injection for the Treatment of Refractory Autoimmune Diseases (ADs)

At a glance
Trial Overview
Trial Details
- Identifiers
- Other Details
Interventions
Trial Centres
- Centres
Trial History
References

Trial Profile

An Early Exploratory Clinical Study of the Safety, Tolerability, and Initial Efficacy of JY231 Injection for the Treatment of Refractory Autoimmune Diseases (ADs)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JY 231 (Primary)
Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Autoimmune disorders; Churg-Strauss syndrome; Dermatomyositis; Granulomatosis with polyangiitis; Microscopic polyangiitis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma
Focus Adverse reactions

Most Recent Events

25 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com